Antiretroviral potential of human tripartite motif-5 and related proteins

Virology

Volumn 353, Issue 2, 2006, Pages 396-409

  Zhang, Fengwen ^a   Hatziioannou, Theodora ^a   Perez Caballero, David ^a   Derse, David ^b   Bieniasz, Paul D ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

HIV 1; Intrinsic immunity; MLV; Retrovirus; SIV; TRIM genes; TRIM5

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEIN DERIVATIVE; TRIM 1 PROTEIN; TRIM 18 PROTEIN; TRIM 19 PROTEIN; TRIM 21 PROTEIN; TRIM 22 PROTEIN; TRIM 34 PROTEIN; TRIM 5 PROTEIN; TRIM 5ALPHA; TRIM 6 PROTEIN; TRIM PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASSAY; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MOUSE; MULTIGENE FAMILY; NONHUMAN; OWL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MOTIF; RETROVIRUS; RNA INTERFERENCE; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS CAPSID; VIRUS INHIBITION; VIRUS STRAIN;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; AOTIDAE; CARRIER PROTEINS; CATS; CELL LINE; HIV INFECTIONS; HIV-1; HUMANS; LENTIVIRUS; LENTIVIRUS INFECTIONS; MEMBRANE PROTEINS; RECOMBINANT PROTEINS; ZINC FINGERS;

AOTUS TRIVIRGATUS; EQUINE INFECTIOUS ANEMIA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MIRIDAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 33748701449     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.05.035     Document Type: Article

References (70)

1. Bainbridge J.W., Stephens C., Parsley K., Demaison C., Halfyard A., Thrasher A.J., and Ali R.R. In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Ther. 8 21 (2001) 1665-1668
2. Baumann J.G., Unutmaz D., Miller M.D., Breun S.K., Grill S.M., Mirro J., Littman D.R., Rein A., and KewalRamani V.N. Murine T cells potently restrict human immunodeficiency virus infection. J. Virol. 78 22 (2004) 12537-12547
3. Best S., Le Tissier P., Towers G., and Stoye J.P. Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 382 6594 (1996) 826-829
4. Bieniasz P.D. Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 5 11 (2004) 1109-1115
5. Bieniasz P.D., Grdina T.A., Bogerd H.P., and Cullen B.R. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J. 17 23 (1998) 7056-7065
6. Bishop K.N., Holmes R.K., Sheehy A.M., Davidson N.O., Cho S.J., and Malim M.H. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14 15 (2004) 1392-1396
7. Bock M., Bishop K.N., Towers G., and Stoye J.P. Use of a transient assay for studying the genetic determinants of Fv1 restriction. J. Virol. 74 16 (2000) 7422-7430
8. Bogerd H.P., Fridell R.A., Blair W.S., and Cullen B.R. Genetic evidence that the Tat proteins of human immunodeficiency virus types 1 and 2 can multimerize in the eukaryotic cell nucleus. J. Virol. 67 8 (1993) 5030-5034
9. Braaten D., Franke E.K., and Luban J. Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV (CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses. J. Virol. 70 7 (1996) 4220-4227
10. Chelbi-Alix M.K., Quignon F., Pelicano L., Koken M.H., and de The H. Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. J. Virol. 72 2 (1998) 1043-1051
11. Cowan S., Hatziioannou T., Cunningham T., Muesing M.A., Gottlinger H.G., and Bieniasz P.D. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc. Natl. Acad. Sci. U.S.A. 99 18 (2002) 11914-11919
12. Derse D., Hill S.A., Lloyd P.A., Chung H., and Morse B.A. Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors. J. Virol. 75 18 (2001) 8461-8468
13. Diaz-Griffero, F., Li, X., Javanbakht, H., Song, B., Welikala, S., Stremlau, M., Sodroski, J., in press. Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology.
14. Doehle B.P., Schafer A., and Cullen B.R. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339 2 (2005) 281-288
15. Garber M.E., Wei P., KewalRamani V.N., Mayall T.P., Herrmann C.H., Rice A.P., Littman D.R., and Jones K.A. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev. 12 22 (1998) 3512-3527
16. Goff S.P. Genetic control of retrovirus susceptibility in mammalian cells. Annu. Rev. Genet. 38 (2004) 61-85
17. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., and Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell 113 6 (2003) 803-809
18. Hatziioannou T., Cowan S., Goff S.P., Bieniasz P.D., and Towers G. Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J. 22 3 (2003) 385-394
19. Hatziioannou T., Cowan S., and Bieniasz P.D. Capsid-dependent and -independent postentry restriction of primate lentivirus tropism in rodent cells. J. Virol. 78 2 (2004) 1006-1011
20. Hatziioannou T., Perez-Caballero D., Yang A., Cowan S., and Bieniasz P.D. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5{alpha}. Proc. Natl. Acad. Sci. U.S.A. 101 29 (2004) 10774-10779
21. Hatziioannou T., Perez-Caballero D., Cowan S., and Bieniasz P.D. Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J. Virol. 79 1 (2005) 176-183
22. Javanbakht H., Diaz-Griffero F., Stremlau M., Si Z., and Sodroski J. The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5alpha. J. Biol. Chem. 280 28 (2005) 26933-26940
23. Keckesova Z., Ylinen L.M., and Towers G.J. The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc. Natl. Acad. Sci. U.S.A. 101 29 (2004) 10780-10785
24. Kozak C.A., and Chakraborti A. Single amino acid changes in the murine leukemia virus capsid protein gene define the target of Fv1 resistance. Virology 225 2 (1996) 300-305
25. Lassaux A., Sitbon M., and Battini J.L. Residues in the murine leukemia virus capsid that differentially govern resistance to mouse Fv1 and human Ref1 restrictions. J. Virol. 79 10 (2005) 6560-6564
26. Lecossier D., Bouchonnet F., Clavel F., and Hance A.J. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300 5622 (2003) 1112
27. Liddament M.T., Brown W.L., Schumacher A.J., and Harris R.S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14 15 (2004) 1385-1391
28. Luban J., Bossolt K.L., Franke E.K., Kalpana G.V., and Goff S.P. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 73 6 (1993) 1067-1078
29. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., and Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424 6944 (2003) 99-103
30. Marchant D., Neil S.J., Aubin K., Schmitz C., and McKnight A. An envelope-determined, pH-independent endocytic route of viral entry determines the susceptibility of human immunodeficiency virus type 1 (HIV-1) and HIV-2 to Lv2 restriction. J. Virol. 79 15 (2005) 9410-9418
31. Martin-Serrano J., Zang T., and Bieniasz P.D. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat. Med. 7 12 (2001) 1313-1319
32. Martin-Serrano J., Eastman S.W., Chung W., and Bieniasz P.D. HECT ubiquitin ligases link viral and cellular PPXY motifs to the vacuolar protein-sorting pathway. J. Cell Biol. 168 1 (2005) 89-101
33. Maul G.G., and Everett R.D. The nuclear location of PML, a cellular member of the C3HC4 zinc-binding domain protein family, is rearranged during herpes simplex virus infection by the C3HC4 viral protein ICP0. J. Gen. Virol. 75 Pt. 6 (1994) 1223-1233
34. Meiering C.D., Comstock K.E., and Linial M.L. Multiple integrations of human foamy virus in persistently infected human erythroleukemia cells. J. Virol. 74 4 (2000) 1718-1726
35. Mitrophanous K., Yoon S., Rohll J., Patil D., Wilkes F., Kim V., Kingsman S., Kingsman A., and Mazarakis N. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther. 6 11 (1999) 1808-1818
36. Nakayama E.E., Miyoshi H., Nagai Y., and Shioda T. A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection. J. Virol. 79 14 (2005) 8870-8877
37. Nisole S., Lynch C., Stoye J.P., and Yap M.W. A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc. Natl. Acad. Sci. U.S.A. 101 36 (2004) 13324-13328
38. Orimo A., Tominaga N., Yoshimura K., Yamauchi Y., Nomura M., Sato M., Nogi Y., Suzuki M., Suzuki H., Ikeda K., Inoue S., and Muramatsu M. Molecular cloning of ring finger protein 21 (RNF21)/interferon-responsive finger protein (ifp1), which possesses two RING-B box-coiled coil domains in tandem. Genomics 69 1 (2000) 143-149
39. Perez-Caballero D., Hatziioannou T., Yang A., Cowan S., and Bieniasz P.D. Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J. Virol. 79 14 (2005) 8969-8978
40. Perez-Caballero D., Hatziioannou T., Zhang F., Cowan S., and Bieniasz P.D. Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J. Virol. 79 24 (2005) 15567-15572
41. Perron M.J., Stremlau M., Song B., Ulm W., Mulligan R.C., and Sodroski J. TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc. Natl. Acad. Sci. U.S.A. 101 32 (2004) 11827-11832
42. Qi C.F., Bonhomme F., Buckler-White A., Buckler C., Orth A., Lander M.R., Chattopadhyay S.K., and Morse III H.C. Molecular phylogeny of Fv1. Mamm. Genome 9 12 (1998) 1049-1055
43. Reuter S., Kaumanns P., Buschhorn S.B., and Dittmar M.T. Role of HIV-2 envelope in Lv2-mediated restriction. Virology 332 1 (2005) 347-358
44. Reymond A., Meroni G., Fantozzi A., Merla G., Cairo S., Luzi L., Riganelli D., Zanaria E., Messali S., Cainarca S., Guffanti A., Minucci S., Pelicci P.G., and Ballabio A. The tripartite motif family identifies cell compartments. EMBO J. 20 9 (2001) 2140-2151
45. Saenz D.T., Teo W., Olsen J.C., and Poeschla E.M. Restriction of feline immunodeficiency virus by Ref1, Lv1, and primate TRIM5alpha proteins. J. Virol. 79 24 (2005) 15175-15188
46. Saphire A.C., Bobardt M.D., and Gallay P.A. Host cyclophilin A mediates HIV-1 attachment to target cells via heparans. EMBO J. 18 23 (1999) 6771-6785
47. Sawyer S.L., Emerman M., and Malik H.S. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2 9 (2004) E275
48. Sawyer S.L., Wu L.I., Emerman M., and Malik H.S. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc. Natl. Acad. Sci. U.S.A. 102 8 (2005) 2832-2837
49. Sayah D.M., Sokolskaja E., Berthoux L., and Luban J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430 (2004) 569-573
50. Schmitz C., Marchant D., Neil S.J., Aubin K., Reuter S., Dittmar M.T., and McKnight A. Lv2, a novel postentry restriction, is mediated by both capsid and envelope. J. Virol. 78 4 (2004) 2006-2016
51. Sebastian S., and Luban J. TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Retrovirology 2 (2005) 40
52. Sheehy A.M., Gaddis N.C., Choi J.D., and Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 6898 (2002) 646-650
53. Sokolskaja E., Sayah D.M., and Luban J. Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J. Virol. 78 23 (2004) 12800-12808
54. Sokolskaja E., Berthoux L., and Luban J. Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J. Virol. 80 6 (2006) 2855-2862
55. Song B., Diaz-Griffero F., Park do H., Rogers T., Stremlau M., and Sodroski J. TRIM5alpha association with cytoplasmic bodies is not required for antiretroviral activity. Virology 343 2 (2005) 201-211
56. Song B., Javanbakht H., Perron M., Park do H., Stremlau M., and Sodroski J. Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. J. Virol. 79 7 (2005) 3930-3937
57. Stevens A., Bock M., Ellis S., LeTissier P., Bishop K.N., Yap M.W., Taylor W., and Stoye J.P. Retroviral capsid determinants of Fv1 NB and NR tropism. J. Virol. 78 18 (2004) 9592-9598
58. Stremlau M., Owens C.M., Perron M.J., Kiessling M., Autissier P., and Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427 6977 (2004) 848-853
59. Stremlau M., Perron M., Welikala S., and Sodroski J. Species-specific variation in the B30.2 (SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J. Virol. 79 5 (2005) 3139-3145
60. Stremlau M., Perron M., Lee M., Li Y., Song B., Javanbakht H., Diaz-Griffero F., Anderson D.J., Sundquist W.I., and Sodroski J. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5{alpha} restriction factor. Proc. Natl. Acad. Sci. U.S.A. 103 14 (2006) 5514-5519
61. Towers G.J., Hatziioannou T., Cowan S., Goff S.P., Luban J., and Bieniasz P.D. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat. Med. 9 9 (2003) 1138-1143
62. Turelli P., Doucas V., Craig E., Mangeat B., Klages N., Evans R., Kalpana G., and Trono D. Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: interference with early steps of viral replication. Mol. Cell 7 6 (2001) 1245-1254
63. Wiegand H.L., Doehle B.P., Bogerd H.P., and Cullen B.R. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23 12 (2004) 2451-2458
64. Yap M.W., Nisole S., Lynch C., and Stoye J.P. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc. Natl. Acad. Sci. U.S.A. 101 29 (2004) 10786-10791
65. Yap M.W., Nisole S., and Stoye J.P. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr. Biol. 15 1 (2005) 73-78
66. Ylinen L.M., Keckesova Z., Wilson S.J., Ranasinghe S., and Towers G.J. Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles. J. Virol. 79 18 (2005) 11580-11587
67. Yoo S., Myszka D.G., Yeh C., McMurray M., Hill C.P., and Sundquist W.I. Molecular recognition in the HIV-1 capsid/cyclophilin A complex. J. Mol. Biol. 269 5 (1997) 780-795
68. Yu Q., Chen D., Konig R., Mariani R., Unutmaz D., and Landau N.R. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem. 279 51 (2004) 53379-53386
69. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., and Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424 6944 (2003) 94-98
70. Zheng Y.H., Irwin D., Kurosu T., Tokunaga K., Sata T., and Peterlin B.M. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78 11 (2004) 6073-6076